Rare disease focus Synageva BioPharma specializes in discovering and delivering medicines for rare diseases with high unmet medical need, presenting a clear market niche for partnerships, licensing, or co-development with specialized biotech and CROs.

Acquisition history The company was acquired by Alexion Pharmaceuticals for 8.4B, indicating strong value and potential interest from large biopharma players in rare-disease portfolios; sales teams should consider strategic outreach to successors and post-merger integration opportunities.

Moderate scale With 11-50 employees and revenue in the mid-range, Synageva presents as a nimble, collaboration-friendly partner suitable for early-stage co-development, manufacturing partnerships, or sponsored research arrangements.

Funding leverage Significant funding raised (approx. 597M) supports continued R&D and rare-disease programs, suggesting readiness for partnership discussions, milestone-driven deals, and access to specialized clinical and regulatory expertise.

Digital footprint Presence on Squarespace and e-commerce tooling indicates a consumer-facing or patient-education component; explore patient-centric programs, educational collaborations, or digital engagement initiatives to broaden clinical trial awareness and advocacy partnerships.